Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
KDR 3791 DOVITINIB CHEMBL522892 inhibitor TALC, TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
KDR 3791 VATALANIB CHEMBL101253 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank, TTD 17584317
KDR 3791 TG100-801 CHEMBL403989 inhibitor ChemblInteractions, DrugBank
KDR 3791 XL-820 CHEMBL3545402 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ChemblInteractions, DrugBank
KDR 3791 IMC-1C11 CHEMBL2109257 DrugBank
KDR 3791 CHEMBL487431 CHEMBL487431 DrugBank 10592235
KDR 3791 AEE-788 CHEMBL587723 inhibitor MyCancerGenome, GuideToPharmacologyInteractions, ChemblInteractions
KDR 3791 ALTIRATINIB CHEMBL3545365 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
KDR 3791 Anlotinib CHEMBL3545021 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
KDR 3791 AST-487 CHEMBL574738 inhibitor GuideToPharmacologyInteractions
KDR 3791 AZD-4547 CHEMBL3184679 inhibitor GuideToPharmacologyInteractions
KDR 3791 BX-795 CHEMBL577784 inhibitor GuideToPharmacologyInteractions
KDR 3791 CEDIRANIB CHEMBL491473 inhibitor MyCancerGenome, ChemblInteractions, GuideToPharmacologyInteractions, TTD, TALC, ClearityFoundationClinicalTrial, TdgClinicalTrial
KDR 3791 ENMD-2076 CHEMBL482968 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
KDR 3791 Fruquintinib CHEMBL3545339 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
KDR 3791 CHEMBL1081312 CHEMBL1081312 inhibitor GuideToPharmacologyInteractions
KDR 3791 SEMAXANIB CHEMBL276711 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
KDR 3791 SU-11652 CHEMBL13485 inhibitor GuideToPharmacologyInteractions
KDR 3791 TAK-659 CHEMBL3544931 inhibitor GuideToPharmacologyInteractions
KDR 3791 CHEMBL101683 CHEMBL101683 inhibitor GuideToPharmacologyInteractions
KDR 3791 AFLIBERCEPT CHEMBL1742982 inhibitor TTD
KDR 3791 MIDOSTAURIN CHEMBL608533 inhibitor MyCancerGenome, ChemblInteractions
KDR 3791 VADIMEZAN CHEMBL71263 TdgClinicalTrial
KDR 3791 TELATINIB CHEMBL2079588 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ChemblInteractions, TTD
KDR 3791 SUNITINIB MALATE CHEMBL1567 inhibitor ChemblInteractions, TTD
KDR 3791 BMS-794833 CHEMBL3545119 inhibitor ChemblInteractions
KDR 3791 Chiauranib CHEMBL3545428 inhibitor ChemblInteractions
KDR 3791 Puquitinib CHEMBL3545088 inhibitor ChemblInteractions
KDR 3791 Henatinib CHEMBL3545416 inhibitor ChemblInteractions
KDR 3791 BRIVANIB ALANINATE CHEMBL270995 inhibitor ChemblInteractions
KDR 3791 CABOZANTINIB S-MALATE CHEMBL2103868 inhibitor ChemblInteractions
KDR 3791 ENMD-981693 CHEMBL52885 inhibitor ChemblInteractions
KDR 3791 TESEVATINIB CHEMBL3544983 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions
KDR 3791 4SC-203 CHEMBL3545358 inhibitor ChemblInteractions, TTD
KDR 3791 XL-999 CHEMBL3545285 inhibitor TALC, TdgClinicalTrial, ChemblInteractions, DrugBank, TTD
KDR 3791 CYC-116 CHEMBL482967 inhibitor TdgClinicalTrial, ChemblInteractions, DrugBank, TTD
KDR 3791 PAZOPANIB CHEMBL477772 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank, MyCancerGenomeClinicalTrial, TTD 17288876
KDR 3791 CHEMBL491429 CHEMBL491429 DrugBank 10592235
KDR 3791 CHEMBL493986 CHEMBL493986 DrugBank 10592235
KDR 3791 GW612286X CHEMBL479079 DrugBank 10592235
KDR 3791 CABOZANTINIB CHEMBL2105717 antagonist, inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, DrugBank, TTD 21606412, 21926191
KDR 3791 BMS-690514 CHEMBL3545396 inhibitor TALC, MyCancerGenome, GuideToPharmacologyInteractions, ChemblInteractions
KDR 3791 JNJ-42756493 CHEMBL3545376 inhibitor GuideToPharmacologyInteractions
KDR 3791 Famitinib CHEMBL3545026 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
KDR 3791 LY-2874455 CHEMBL3545264 inhibitor GuideToPharmacologyInteractions
KDR 3791 MK-2461 CHEMBL1822792 inhibitor GuideToPharmacologyInteractions
KDR 3791 TIVOZANIB CHEMBL1289494 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
KDR 3791 CHEMBL92461 CHEMBL92461 inhibitor GuideToPharmacologyInteractions
KDR 3791 MGCD-265 CHEMBL254760 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ChemblInteractions
KDR 3791 KRN-633 CHEMBL406381 inhibitor ChemblInteractions, TTD
KDR 3791 Pexmetinib CHEMBL3545297 TdgClinicalTrial
KDR 3791 CHEMBL313417 CHEMBL313417 TdgClinicalTrial
KDR 3791 SORAFENIB TOSYLATE CHEMBL1200485 inhibitor ChemblInteractions, MyCancerGenomeClinicalTrial
KDR 3791 NINTEDANIB ESYLATE CHEMBL3039504 inhibitor ChemblInteractions
KDR 3791 L-21649 CHEMBL3544927 inhibitor ChemblInteractions
KDR 3791 PF-00337210 CHEMBL3545136 inhibitor ChemblInteractions
KDR 3791 ZD-4190 (CHEMBL3544937) CHEMBL3544937 inhibitor ChemblInteractions
KDR 3791 ALACIZUMAB PEGOL CHEMBL1742983 antagonist ChemblInteractions
KDR 3791 CM-082 CHEMBL3545427 inhibitor ChemblInteractions
KDR 3791 SUNITINIB CHEMBL535 inhibitor TEND, CIViC, DrugBank, GuideToPharmacologyInteractions, TTD, TdgClinicalTrial, TALC, MyCancerGenome, MyCancerGenomeClinicalTrial, CKB 19723655, 16533791, 12538485, 14753710, 11752352, 12873999, 16418310, 20142593, 27149458, 28011623
KDR 3791 CHEMBL504805 CHEMBL504805 DrugBank 10592235
KDR 3791 REGORAFENIB CHEMBL1946170 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, CKB, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank, MyCancerGenomeClinicalTrial 27004155
KDR 3791 NINTEDANIB CHEMBL502835 inhibitor, Inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, DrugBank 18559524
KDR 3791 CEP-11981 CHEMBL2010872 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
KDR 3791 CLOFIBRATE CHEMBL565 inhibitor GuideToPharmacologyInteractions
KDR 3791 GOLVATINIB CHEMBL3039525 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
KDR 3791 CHEMBL1908396 CHEMBL1908396 inhibitor GuideToPharmacologyInteractions
KDR 3791 ORANTINIB CHEMBL274654 inhibitor TALC, MyCancerGenome, GuideToPharmacologyInteractions, ChemblInteractions, TTD
KDR 3791 PLX-3397 CHEMBL3545158 inhibitor GuideToPharmacologyInteractions
KDR 3791 CHEMBL88606 CHEMBL88606 inhibitor GuideToPharmacologyInteractions
KDR 3791 CHEMBL2141478 CHEMBL2141478 inhibitor TALC
KDR 3791 PEGPLERANIB SODIUM CHEMBL3301576 TdgClinicalTrial
KDR 3791 CEP-7055 CHEMBL346631 inhibitor ChemblInteractions, TTD
KDR 3791 CHIR-265 CHEMBL558752 inhibitor MyCancerGenome, TdgClinicalTrial, ChemblInteractions
KDR 3791 X-82 CHEMBL3545401 inhibitor MyCancerGenome, ChemblInteractions
KDR 3791 PAZOPANIB HYDROCHLORIDE CHEMBL1201733 inhibitor ChemblInteractions, TTD
KDR 3791 MOTESANIB DIPHOSPHATE CHEMBL2107357 inhibitor TTD
KDR 3791 CETUXIMAB CHEMBL1201577 CKB 27149458
KDR 3791 LENVATINIB MESYLATE CHEMBL2105704 inhibitor ChemblInteractions
KDR 3791 Sulfatinib CHEMBL3545251 inhibitor ChemblInteractions
KDR 3791 RG-1530 CHEMBL1980391 inhibitor ChemblInteractions
KDR 3791 JI-101 CHEMBL3545155 inhibitor ChemblInteractions
KDR 3791 CP-459632 CHEMBL3545300 inhibitor ChemblInteractions
KDR 3791 SORAFENIB CHEMBL1336 antagonist, inhibitor GuideToPharmacologyInteractions, TdgClinicalTrial, TALC, CKB, DrugBank, MyCancerGenome, TEND, ClearityFoundationClinicalTrial, MyCancerGenomeClinicalTrial, CIViC 19723655, 16824050, 16503817, 16446323, 16757355, 16418310
KDR 3791 FORETINIB CHEMBL1230609 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank, TTD
KDR 3791 LINIFANIB CHEMBL223360 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank
KDR 3791 AXITINIB CHEMBL1289926 inhibitor DrugBank, GuideToPharmacologyInteractions, TTD, ChemblInteractions, TALC, PharmGKB, CancerCommons, MyCancerGenomeClinicalTrial, MyCancerGenome, TdgClinicalTrial 18541897
KDR 3791 CHEMBL394826 CHEMBL394826 DrugBank 10592235
KDR 3791 CHEMBL385178 CHEMBL385178 DrugBank 10592235
KDR 3791 CHEMBL272198 CHEMBL272198 DrugBank 10592235
KDR 3791 CHEMBL194176 CHEMBL194176 DrugBank 10592235
KDR 3791 INFIGRATINIB CHEMBL1852688 inhibitor GuideToPharmacologyInteractions
KDR 3791 BRIVANIB CHEMBL377300 inhibitor TALC, PharmGKB, MyCancerGenome, GuideToPharmacologyInteractions, ChemblInteractions
KDR 3791 OSI-632 CHEMBL253969 inhibitor GuideToPharmacologyInteractions, ChemblInteractions, TTD
KDR 3791 DORSOMORPHIN CHEMBL478629 inhibitor GuideToPharmacologyInteractions
KDR 3791 LENVATINIB CHEMBL1289601 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, TTD
KDR 3791 LUCITANIB CHEMBL2220486 inhibitor CKB, GuideToPharmacologyInteractions, ChemblInteractions, MyCancerGenomeClinicalTrial 25193991
KDR 3791 OSI-930 CHEMBL1614710 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TTD
KDR 3791 PLX-4720 CHEMBL1230020 inhibitor GuideToPharmacologyInteractions
KDR 3791 SU-14813 CHEMBL3545160 inhibitor GuideToPharmacologyInteractions, ChemblInteractions, TTD
KDR 3791 TABERMINOGENE VADENOVEC CHEMBL2108065 TdgClinicalTrial
KDR 3791 SU-014813 CHEMBL1721885 inhibitor ChemblInteractions
KDR 3791 CEP-5214 CHEMBL150894 inhibitor ChemblInteractions
KDR 3791 TAK-593 CHEMBL2180604 inhibitor ChemblInteractions
KDR 3791 AG-13958 CHEMBL3545335 inhibitor ChemblInteractions
KDR 3791 TELBERMIN CHEMBL2108557 agonist ChemblInteractions
KDR 3791 BMS-817378 CHEMBL3545050 inhibitor ChemblInteractions
KDR 3791 ILORASERTIB CHEMBL1980297 inhibitor ChemblInteractions
KDR 3791 PONATINIB CHEMBL1171837 inhibitor MyCancerGenome, DrugBank 19878872
KDR 3791 RAMUCIRUMAB CHEMBL1743062 antagonist, inhibitor, antibody TALC, MyCancerGenome, TdgClinicalTrial, CKB, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 2182794, 20048182
KDR 3791 MOTESANIB CHEMBL572881 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, CKB, GuideToPharmacologyInteractions, ChemblInteractions, TTD 21422803
KDR 3791 VANDETANIB CHEMBL24828 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ClearityFoundationClinicalTrial, CKB, GuideToPharmacologyInteractions, ChemblInteractions, MyCancerGenomeClinicalTrial, TTD 26578684
KDR 3791 TAS-115 CHEMBL3545144 inhibitor CKB, ChemblInteractions 24140932
KDR 3791 GEMCITABINE CHEMBL888 CKB 19930156

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
KDR rs2071559 AG ranibizumab efficacy no Response was measured by improvement in mean visual acuity, using either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections. Genotype AG is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype GG. 22840423 981755320
KDR rs34231037 AG sunitinib efficacy yes Clinical benefit as defined by the comparison of CR (complete response), PR (partial response), SD (stable disease) > 1 year vs. PD (progressive disease), SD < 1 year. Genotype AG is associated with increased clinical benefit to sunitinib as compared to genotype GG. 28430711 1448615381
KDR rs2071559 AA ranibizumab efficacy no Response was measured by improvement in mean visual acuity, using either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections. Genotype AA is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype GG. 22840423 981755314
KDR rs7667298 C clopidogrel efficacy no There were no significant differences in the genotype and allele frequency of VEGFR-2 rs1870377 polymorphism or rs7667298 polymorphism between CR (clopidogrel resistant) group and the NGR group (p>0.05). Allele C is not associated with decreased response to clopidogrel in people with Coronary Disease as compared to allele T. 25738571 1444697594
KDR rs2305948 CT + TT cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes CT + TT are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CC. 24090479 1183701018
KDR rs7671745 GG ranibizumab efficacy no Response was measured by improvement in mean visual acuity, using either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections. Genotype GG is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype AA. 22840423 981755326
KDR rs7671745 AG ranibizumab efficacy no Response was measured by improvement in mean visual acuity, using either Snellen or Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity tests. Visual acuity was measured at baseline and after three monthly intravitreal ranibizumab injections. Genotype AG is not associated with response to ranibizumab in people with Macular Degeneration as compared to genotype AA. 22840423 981755333
KDR rs2071559 AG + GG cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes AG + GG are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype AA. 24090479 1183701007
KDR rs7667298 CC + CT cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes CC + CT are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype TT. 24090479 1183701023
KDR rs2305948 CT sunitinib efficacy no The genotype was not associated with clinical benefit, which was defined as either partial response or stable disease. The genotype was also not associated with progression free survival, or overall survival. Genotype CT is not associated with response to sunitinib in people with Carcinoma, Renal Cell as compared to genotype CC. 26244574 1446695874
KDR rs2071559 AA + AG ranibizumab efficacy yes as measured by improvement in mean retinal sensitivity but was not significant when measured by best corrected visual acuity or other methods. Genotypes AA + AG is associated with decreased response to ranibizumab in people with Macular Degeneration as compared to genotype GG. 26653034 1447676351
KDR rs1870377 AT + TT carfilzomib efficacy yes as measured by "minimum residual disease negativity" (MRD-). Gene is on negative strand, alleles complemented to positive strand. Authors reported for response associated allele as protein change as 472Q. Genotypes AT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype AA. 28488026 1448634666
KDR rs2305948 CT + TT carfilzomib efficacy yes Authors indicate repose as CR/nCR/sCR but do not define these and non-response as VGPR and PR/SD (which assume to mean progression/stable disease). There was only one TT individual who had sCR. Genotypes CT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC. 28488026 1448634657
KDR rs1870377 T imatinib dosage no No significant association between genotype and chance of requiring an imatinib dose reduction. Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A. 30713339 1450933505
KDR rs2305948 CT imatinib dosage no No significant association between genotype and chance of requiring an imatinib dose reduction. Genotype CT is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC. 30713339 1450933522
KDR rs34231037 AG pazopanib efficacy yes Patients with the G allele had greater decline over 4 weeks in [sVEGFR2] with pazopanib exposure compared to non-carriers (mean decrease -3.5ng/mL vs -2.3 ng/mL, they also had lower baseline [sVEGFR2] measures. Serum VEGFR2 concentrations [sVEGFR2] is a pharmacodynamic biomarker for VEGFR2 inhibitors. No GG homozygotes were shown. Genotype AG is associated with increased response to pazopanib in people with Carcinoma, Renal Cell as compared to genotype AA. 25411163 1185002754
KDR rs34231037 AG sunitinib efficacy no Response defined by the comparison of CR (complete response), PR (partial response) vs SD (stable disease) PD (progressive disease) Genotype AG is associated with response to sunitinib as compared to genotype GG. 28430711 1448615387
KDR rs1870377 AA + AT cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes AA + AT are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype TT. 24090479 1183700999
KDR rs1870377 A clopidogrel efficacy no There were no significant differences in the genotype and allele frequency of VEGFR-2 rs1870377 polymorphism or rs7667298 polymorphism between CR (clopidogrel resistant) group and the NGR group (p>0.05). Allele A is not associated with decreased response to clopidogrel in people with Coronary Disease as compared to allele T. 25738571 1444697587
KDR rs2071559 A ranibizumab efficacy no Age-related macular degeneration. No significant differences in best-corrected visual acuity (BCVA) changes or central subfield macular thickness (CSMT) changes were seen between baseline and 3 or 6 months of treatment between any of the genotypes. Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G. 23559864 1183682059
KDR rs2071559 A imatinib dosage no No significant association between genotype and chance of requiring an imatinib dose reduction. Please note that alleles have been complemented to the positive strand. Allele A is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G. 30713339 1450933513
KDR rs2305948 T clopidogrel efficacy yes Genotype and allele frequency of VEGFR-2 rs2305948 was significantly higher in the CR (clopidogrel resistant) group than in the NCR group (TT: 55.9% vs. 36.1%, P<0.05; T allele: 78.5% vs. 66.8%,P<0.01, respectively). Allele T is associated with decreased response to clopidogrel in people with Coronary Disease as compared to allele C. 25738571 1444697577